TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15561256

Group type: EXPERIMENTAL
Intervention: Tacrolimus (TAC)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Cyclosporine (CsA)
Number of subjects: 21
Study: 11379836

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 1637

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 1637

Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 1637
Study: 9642379

Group type: EXPERIMENTAL
Intervention: Low-dose magnesium gluconate (3 g/day)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study: 3556202

Group type: EXPERIMENTAL
Intervention: High-dose budesonide (1600 micrograms/day)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Low-dose budesonide (400 micrograms/day)
Number of subjects: 24
Study: 30368346

Group type: EXPERIMENTAL
Intervention: Pilates Reformer intervention
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 55
Study: 27400657

Group type: EXPERIMENTAL
Intervention: Mandatory intervention providing all general practitioners with a starting package of 10 iFOBTs, clinical instruction on iFOBT use, and online information material; optional continuous medical education on colorectal cancer diagnostics and use of iFOBT.
Number of subjects: 836
Study: 26578370

Group type: EXPERIMENTAL
Intervention: OsteoACTIVE (exercise programme and patient education)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Patient education only (control group)
Number of subjects: 80
Study: 23896630

Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiotherapy (IMRT)
Number of subjects: 57

Group type: COMPARATOR
Intervention: 3D Conformal Radiotherapy (3D-RT)
Number of subjects: 57
Study: 20034362

Group type: EXPERIMENTAL
Intervention: Pravastatin 20 mg
Number of subjects: 49

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 49
Study: 18840378

Group type: EXPERIMENTAL
Intervention: Low fresh gas flow balanced anesthesia (LFGF SS) with inhalational sevoflurane and IV sufentanil in a target controlled infusion
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Low fresh gas flow balanced anesthesia (LFGF SS)
Number of subjects: 60

Group type: COMPARATOR
Intervention: IV anesthesia (TCI)
Number of subjects: 60
Study: 16373160

Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation and plication
Number of subjects: 700

Group type: COMPARATOR
Intervention: Milligan‐Morgan hemorrhoidectomy
Number of subjects: 700
Study: 12798559

Group type: EXPERIMENTAL
Intervention: Atrial prevention and antitachycardia pacing (ATP) ON
Number of subjects: 368

Group type: COMPARATOR
Intervention: DDDR pacing at a lower programmed rate of 60 ppm (OFF group)
Number of subjects: 368
Study: 11119738

Group type: EXPERIMENTAL
Intervention: IVF
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control (normal menstrual cycle)
Number of subjects: 71
Study: 8841162

Group type: EXPERIMENTAL
Intervention: Medical nutrition therapy from a registered dietitian (one or three visits) in addition to physician or nurse counseling and Grocery Shopping Guide.
Number of subjects: 104

Group type: COMPARATOR
Intervention: Counseling by a physician or nurse (control group).
Number of subjects: 104
Study: 1634641

Group type: EXPERIMENTAL
Intervention: Lovastatin
Number of subjects: 35
Study: 6662159

Group type: COMPARATOR
Intervention: Clonidine (0.3 mg p.o.)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Clonidine (0.3 mg p.o.) plus maprotiline (100 mg in 4 divided doses over 22 h)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Maprotiline (100 mg in 4 divided doses over 22 h)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 30845034

Group type: EXPERIMENTAL
Intervention: Sacroiliac joint arthrodesis with triangular titanium implants
Number of subjects: 103

Group type: COMPARATOR
Intervention: Conservative management
Number of subjects: 103
Study: 28391703

Group type: EXPERIMENTAL
Intervention: MyFamilyPlan online preconception health education module
Number of subjects: 292

Group type: COMPARATOR
Intervention: Standard online preconception health education materials (Control)
Number of subjects: 292
Study: 26318445

Group type: EXPERIMENTAL
Intervention: Ginger (2 g/day of ginger powder for 12 weeks)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo (corn starch as two 1 g tablets for 12 weeks)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Ginger
Number of subjects: 80
Study: 25257359

Group type: EXPERIMENTAL
Intervention: Single-dose 300,000-IU intramuscular injection of vitamin D3
Number of subjects: 380

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 380
Study: 22643160

Group type: EXPERIMENTAL
Intervention: Exercise (minimum of 20 minutes, three times per week, at 55% of maximal aerobic capacity)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 60
Study: 20705215

Group type: EXPERIMENTAL
Intervention: Tricyclic antidepressants
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Serotonin noradrenaline reuptake inhibitors
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Opioids
Number of subjects: 174

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 174
Study: 17186393

Group type: EXPERIMENTAL
Intervention: Warfarin at target INR range of 2.1-3.0
Number of subjects: 114

Group type: COMPARATOR
Intervention: Warfarin at target INR range of 3.1-4.0
Number of subjects: 114
Study: 15110397

Group type: EXPERIMENTAL
Intervention: Antioxidants (AO: 1000 mg vitamin C and 300 mg RRR‐alpha‐tocopheryl acetate)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebos (PL)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Antioxidants (AO)
Number of subjects: 22
Study: 12235304

Group type: EXPERIMENTAL
Intervention: Learning test (memory)
Number of subjects: 5804

Group type: EXPERIMENTAL
Intervention: Coding test (general speed)
Number of subjects: 5804

Group type: EXPERIMENTAL
Intervention: Short version of the Stroop test (attention)
Number of subjects: 5804

Group type: EXPERIMENTAL
Intervention: All tests
Number of subjects: 5804
Study: 9680495

Group type: EXPERIMENTAL
Intervention: Albuterol (200 micrograms administered via a Volumatic spacer)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Carbachol responsiveness
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Prophylactic anti-inflammatory treatment
Number of subjects: 46
Study: 8205569

Group type: EXPERIMENTAL
Intervention: Hemopump cardiac assist system
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hemopump for circulatory support during aorto-coronary artery surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hemopump for high-risk angioplasty
Number of subjects: 0
Study: 2643863

Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (in combination)
Number of subjects: 0
Study: 31790853

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural case management (CBCM)
Number of subjects: 304
Study: 29930261

Group type: EXPERIMENTAL
Intervention: Intramuscular (IM) injections
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Intranasal (IN) injections
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Subcutaneous (SC) injections
Number of subjects: 24

Group type: COMPARATOR
Intervention: Null control
Number of subjects: 24
Study: 29203734

Group type: EXPERIMENTAL
Intervention: Pioglitazone (15 mg once daily for 6 months)
Number of subjects: 43
Study: 25600818

Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cathodal tDCS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cathodal and anodal stimulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: tDCS (both anodal and cathodal)
Number of subjects: 0
Study: 24016492

Group type: EXPERIMENTAL
Intervention: Usual care plus early rhythm control therapy (antiarrhythmic drugs, catheter ablation, and patient-operated ECG device)
Number of subjects: 3000

Group type: COMPARATOR
Intervention: Usual care (anticoagulation, therapy of underlying heart disease, and rate control)
Number of subjects: 3000

Group type: EXPERIMENTAL
Intervention: Usual care plus early rhythm control therapy
Number of subjects: 3000
Study: 21085884

Group type: EXPERIMENTAL
Intervention: Educational intervention (telephone interviews and workshops)
Number of subjects: 1467

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1467
Study: 18031595

Group type: EXPERIMENTAL
Intervention: Pramlintide (60 or 120 mcg with major meals)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Pramlintide
Number of subjects: 211
Study: 16749292

Group type: EXPERIMENTAL
Intervention: Educational interventions targeting cardiologists
Number of subjects: 0

Group type: COMPARATOR
Intervention: Guideline recommendations for acute coronary syndromes
Number of subjects: 0
Study: 14579210

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 295

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 295
Study: 10762522

Group type: COMPARATOR
Intervention: CSF ferritin levels
Number of subjects: 16

Group type: COMPARATOR
Intervention: CSF transferrin levels
Number of subjects: 16
Study: 8653096

Group type: EXPERIMENTAL
Intervention: Imagery study task during initial study period
Number of subjects: 0
Study: 1450143

Group type: EXPERIMENTAL
Intervention: Retrievette
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Emmett
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Mi-Mark Helix
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: First plastic retriever
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Second plastic retriever
Number of subjects: 217

Group type: COMPARATOR
Intervention: Spencer Wells forceps
Number of subjects: 217
Study: 2409990

Group type: EXPERIMENTAL
Intervention: Intravenous ethanol (10% v/v; 300 mg kg‐1 body weight for 30 min followed by 3 mg kg‐1 min‐1 for 2 hr)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Intravenous NaCl (0.15 M)
Number of subjects: 6
Study: 30565779

Group type: EXPERIMENTAL
Intervention: Statin initiation in women with total cholesterol > 240 mg/dL vs < 200 mg/dL during ATP-II period
Number of subjects: 34382

Group type: EXPERIMENTAL
Intervention: Statin initiation in women with total cholesterol > 240 mg/dL vs < 200 mg/dL during ATP-III period
Number of subjects: 34382

Group type: EXPERIMENTAL
Intervention: Statin initiation in women with diabetes for primary prevention
Number of subjects: 34382

Group type: EXPERIMENTAL
Intervention: Statin initiation in women with diabetes for secondary prevention
Number of subjects: 34382

Group type: EXPERIMENTAL
Intervention: Statin initiation in women with diabetes before ATP-III
Number of subjects: 34382

Group type: EXPERIMENTAL
Intervention: Statin initiation in women with diabetes after ATP-III
Number of subjects: 34382
Study: 29124959

Group type: EXPERIMENTAL
Intervention: Auditory-motor integration prepractice
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Phonological planning prepractice
Number of subjects: 1

Group type: COMPARATOR
Intervention: Control condition (no prepractice)
Number of subjects: 1
Study: 26879784

Group type: EXPERIMENTAL
Intervention: Quadruple regimen (rabeprazole + amoxicillin + clarithromycin + bismuth potassium citrate) for 10 days followed by bismuth-placebo for 21 days (Group A1)
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: Quadruple regimen (rabeprazole + amoxicillin + clarithromycin + bismuth potassium citrate) for 10 days followed by bismuth potassium citrate for 21 days (Group A2)
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: Quadruple regimen for 10 days followed by rabeprazole for 14 days in duodenal ulcer patients
Number of subjects: 430

Group type: COMPARATOR
Intervention: Symptoms improvement status (pain, burning sensation, reflux, belching, nausea, and vomiting)
Number of subjects: 430
Study: 24658878

Group type: EXPERIMENTAL
Intervention: Deception condition (initially told 6 MVCs, then asked to perform 12)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control condition (informed of 12 MVCs)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Unknown condition (not informed of MVCs, stopped after 12)
Number of subjects: 30
Study: 22311056

Group type: EXPERIMENTAL
Intervention: Onabotulinum toxin A (100-125 U)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 20579305

Group type: EXPERIMENTAL
Intervention: Preprocedure CTA review
Number of subjects: 26

Group type: COMPARATOR
Intervention: No preprocedure CTA review
Number of subjects: 26
Study: 18820977

Group type: EXPERIMENTAL
Intervention: Oral polyethylene glycol (Group A)
Number of subjects: 129

Group type: COMPARATOR
Intervention: No mechanical bowel preparation (Group B)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Combined complications (SSI and anastomotic failure) (Group A)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Combined complications (SSI and anastomotic failure) (Group B)
Number of subjects: 129
Study: 16076330

Group type: EXPERIMENTAL
Intervention: Gastrografin
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 11974895

Group type: EXPERIMENTAL
Intervention: High-flow inhalation of fluticasone dipropionate (DFP) (> 100 L/min)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Medium-flow inhalation of fluticasone dipropionate (DFP) (70 L/min)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Beclomethasone (BDP)
Number of subjects: 13
Study: 10447899

Group type: EXPERIMENTAL
Intervention: atropine+meperidine
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: glycopyrrolate+meperidine
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: diazepam
Number of subjects: 76

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 76
Study: 7772974

Group type: EXPERIMENTAL
Intervention: Topical anesthesia (nebulized 4% lidocaine, 20 ml via oropharynx + transtracheal injection of 4% lidocaine, 3 ml)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Nerve block (bilateral glossopharyngeal and superior laryngeal nerve blocks with 2% lidocaine, 0.5‐2 ml per injection site + transtracheal injection of 4% lidocaine, 3 ml)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 2182430

Group type: EXPERIMENTAL
Intervention: L10 protocol
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: L10M protocol
Number of subjects: 250

Group type: COMPARATOR
Intervention: L2 protocol
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Complete remission (CR)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Disease-free survival
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Relapse rates after continuous CR
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Postrelapse survival
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Treatment in second or later remission
Number of subjects: 250
Study: 219267

Group type: EXPERIMENTAL
Intervention: Thymosin fraction V, 60 mg/sq m, twice weekly during the initial six weeks of chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thymosin fraction V, 20 mg/sq m, twice weekly during the initial six weeks of chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: No thymosin treatment during the initial six weeks of chemotherapy
Number of subjects: 0
Study: 31680138

Group type: EXPERIMENTAL
Intervention: High-carb test meal (MTT-HC) at 09:00 and high-fat meal (MTT-HF) at 15:40
Number of subjects: 29

Group type: COMPARATOR
Intervention: High-fat meal (MTT-HF) at 09:00 and high-carb test meal (MTT-HC) at 15:40
Number of subjects: 29
Study: 30339627

Group type: EXPERIMENTAL
Intervention: Gemcitabine (GEM) at a dosage of 1000 mg/m every 2 weeks for 6 months
Number of subjects: 70

Group type: COMPARATOR
Intervention: S-1 at a dosage of 80 mg/m/d for 28 days every 6 weeks for 6 months
Number of subjects: 70
Study: 27223884

Group type: EXPERIMENTAL
Intervention: Nurse-led Internet-based Learning and Self-care program
Number of subjects: 0
Study: 26022410

Group type: EXPERIMENTAL
Intervention: CBASP (22 sessions)
Number of subjects: 60

Group type: COMPARATOR
Intervention: ESC plus clinical management (ESC/CM)
Number of subjects: 60
Study: 23202265

Group type: EXPERIMENTAL
Intervention: Conditional cancer treatment subsidy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reduced price of screening by 10 cents
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 21998346

Group type: EXPERIMENTAL
Intervention: Multidimensional lifestyle intervention
Number of subjects: 652

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 652
Study: 18287375

Group type: EXPERIMENTAL
Intervention: Food plus micronutrient capsule (MN) containing 30 mg iron/d
Number of subjects: 61

Group type: COMPARATOR
Intervention: Food supplement (control group)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: No inflammation group (baseline and 3 months)
Number of subjects: 61
Study: 17668991

Group type: EXPERIMENTAL
Intervention: Prenatal screening offered
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Prenatal screening refused
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: False negative result on screening
Number of subjects: 97
Study: 12838091

Group type: EXPERIMENTAL
Intervention: Classification-based physical therapy
Number of subjects: 78

Group type: COMPARATOR
Intervention: Guideline-based therapy
Number of subjects: 78

Group type: COMPARATOR
Intervention: Classification-based therapy
Number of subjects: 78
Study: 10846913

Group type: EXPERIMENTAL
Intervention: Tramadol 100 mg every 6 hours intravenously
Number of subjects: 76

Group type: COMPARATOR
Intervention: Ketorolac 30 mg every 6 hours intravenously
Number of subjects: 76
Study: 9171907

Group type: EXPERIMENTAL
Intervention: Interpersonal and social rhythm therapy (IPSRT)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Medication clinic approach
Number of subjects: 38
Study: 1303845

Group type: EXPERIMENTAL
Intervention: Benadryl before the first transfusion
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Hydrocortisone before the second transfusion
Number of subjects: 73

Group type: COMPARATOR
Intervention: Hydrocortisone before the first transfusion
Number of subjects: 73

Group type: COMPARATOR
Intervention: Benadryl before the second transfusion
Number of subjects: 73
Study: 3971390

Group type: EXPERIMENTAL
Intervention: Vinca alkaloids (VA)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control (no VA)
Number of subjects: 63
Study: 29420360

Group type: EXPERIMENTAL
Intervention: REAL+RAT (20 min of real dual-tDCS associated with RAT)
Number of subjects: 21

Group type: COMPARATOR
Intervention: SHAM+RAT (20 min of sham dual-tDCS associated with RAT)
Number of subjects: 21
Study: 27129767

Group type: EXPERIMENTAL
Intervention: Rezūm System thermal therapy (thermal water vapor at 103°C)
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Rezūm System thermal therapy
Number of subjects: 197

Group type: COMPARATOR
Intervention: Control (rigid cystoscopy with simulated active treatment sounds)
Number of subjects: 197
Study: 24385026

Group type: EXPERIMENTAL
Intervention: Subcutaneous passive drainage
Number of subjects: 246

Group type: COMPARATOR
Intervention: No drainage
Number of subjects: 246
Study: 22248352

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol (200/6 µg, two inhalations bd)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Budesonide (200 µg, two inhalations bd)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol
Number of subjects: 50
Study: 20457579

Group type: EXPERIMENTAL
Intervention: Proactive home visits by trained community nurses
Number of subjects: 651

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 651
Study: 18777420

Group type: EXPERIMENTAL
Intervention: Clinical attachment in Primary Health Care (1-week duration)
Number of subjects: 0
Study: 16024853

Group type: EXPERIMENTAL
Intervention: Intravitreal triamcinolone acetonide 2 mg
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Intravitreal triamcinolone acetonide 5 mg
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Intravitreal triamcinolone acetonide 13 mg
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Intravitreal triamcinolone acetonide (all dosages)
Number of subjects: 27
Study: 12465720

Group type: EXPERIMENTAL
Intervention: Balloon treatment for 13 weeks followed by balloon for 52 weeks
Number of subjects: 42

Group type: COMPARATOR
Intervention: Sham treatment for 13 weeks followed by balloon for 52 weeks
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Balloon treatment for 52 weeks
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Weight loss (not specified how achieved)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 42
Study: 10591384

Group type: EXPERIMENTAL
Intervention: 0.9 mg/kg of rt-PA (n = 272)
Number of subjects: 613

Group type: COMPARATOR
Intervention: Placebo (n = 275)
Number of subjects: 613

Group type: EXPERIMENTAL
Intervention: 0.9 mg/kg of rt-PA
Number of subjects: 613

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 613
Study: 9121997

Group type: EXPERIMENTAL
Intervention: Genotype E2O in hypertensives
Number of subjects: 134

Group type: COMPARATOR
Intervention: Genotype E2O in normotensives
Number of subjects: 134

Group type: COMPARATOR
Intervention: MspI and HindIII RFLP analysis
Number of subjects: 134

Group type: COMPARATOR
Intervention: EcoT141 RFLP analysis
Number of subjects: 134
Study: 1655262

Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 874

Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 874

Group type: COMPARATOR
Intervention: Captopril
Number of subjects: 874

Group type: EXPERIMENTAL
Intervention: Lisinopril, Enalapril, Captopril
Number of subjects: 874
Study: 6809108

Group type: EXPERIMENTAL
Intervention: Kanga pant with Kanga pad
Number of subjects: 51

Group type: COMPARATOR
Intervention: Sandra pant with Bambi pad
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Kanga pant
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Bambi pad
Number of subjects: 51
Study: 31994638

Group type: EXPERIMENTAL
Intervention: Tamojunto drug use prevention program
Number of subjects: 6176
Study: 30578922

Group type: EXPERIMENTAL
Intervention: Depressive symptoms
Number of subjects: 277